Sequential Moderate Hypofractionated Boost in Breast Cancer Patients: A Monoinstitutional Analysis of Late Side Effects.

Isabella PalumboAnna Giulia BecchettiElisabetta PerrucciLorenzo FalcinelliSimonetta SaldiVittorio BiniCynthia Aristei

Published in: Anticancer research (2024)

HB after HF-WBI was safe and well-tolerated, even at a long-term follow-up; consequently, it can be used in routine practice.

Keyphrases